The development of a point-of-care device able to measure D-dimer and GFAP rapidly (e.g., <10 min), as well as to automatically combine field-collected stroke severity scales in an algorithm, would be required to implement our diagnostic strategy in the clinic. This evidence concerns the gene GFAP and Stroke.